Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug candidate focused on infectious disease. Currently, most of Emergent's business comes from government contracts for biodefense. Emergent will acquire PSC's ongoing operations, including FluBlok, a Phase III recombinant influenza vaccine candidate, and certain other assets. "The acquisition of FluBlok is consistent with Emergent's strategy of expanding its product portfolio with a vaccine candidate focused on a major infectious disease," said Fuad El-Hibri, Emergent's CEO. The company recently bought rival VaxGen's anthrax vaccine business.
- check out Emergent's release [1]
- read the Washington Post article [2]
Related Articles:
Emergent BioSolutions files $86M IPO
Struggling VaxGen sells anthrax vaccine to rival [3]
Links:
[1] http://www.fiercebiotech.com/press-releases/emergent-biosolutions-acquire-protein-sciences-phase-iii-recombinant-flu-vaccine-cand
[2] http://www.washingtonpost.com/wp-dyn/content/article/2008/05/26/AR2008052601761.html
[3] http://www.fiercebiotech.com/story/emergent-biosolutions-files-86m-ipo/2006-08-15